News
News
T-1201 get 2017 Taipei Biotech Award_ Technology Transfer Gold Medal Award
Taivex corporate with Institute of Biotechnology and Pharmaceutical Research (IBPR) at National Health Research Institute, developing a first-in-class small molecule drug, T-1201. This drug had received 2016 Technology Achievement Award (Ministry of Economic Affairs), now get 2017 Taipei Biotech Award_ Technology Transfer Gold Medal Award (Taipei City Government). T-1201 is a noval anti-tumor drug deliver system, that with intellectual property …
T-1101 OPC approved by the TFDA to start Phase I clinical study
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 IND application has been approved by FDA in Sept, 2016 and further by TFDA in Jan, 2017. T-1101 acts through disrupting the interaction between Hec1 and Nek2, these proteins involved in mitotic regulation that are highly expressed in cancer cells. …
First in the worldwide! Oral powder T-1101 approved by the US FDA to start Phase I clinical study
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 Investigational New Drug Application (IND) has been submitted in Aug, 2016 and approved by FDA in Sept, 2016. T-1101 is novel oral powder dosage Hec1/Nek2 inhibitor, which block the interaction of Hec1/Nek2 during tumor cell division and lead tumor …
T-1201 (DBPR115) Technique transfer from National Health Research Institute (NHRI)
Taivex Therapeutics Corporation (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1201 (formerly, DBPR115), a potential anti-cancer developmental drug candidate, effective on Augest 18, 2016.This targeting drug, T-1201 could deliver the itself to the tumor site and make the drug accumulated at the tumor site. Increasing the drug concentration around the tumor …
